[ad_1]
Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2024 Earnings Convention Name November 6, 2024 4:30 PM ET
Firm Contributors
Ryan Asay – Senior Vice President-Company AffairsMark Goldsmith – Chairman and Chief Government OfficerSteve Kelsey – President-Analysis and DevelopmentJack Anders – Chief Monetary OfficerWei Lin – Chief Medical Officer
Convention Name Contributors
Peter Lawson – BarclaysMichael Schmidt – Guggenheim SecuritiesJay Olson – OppenheimerMarc Frahm – TD CowenAlec Stranahan – Financial institution of AmericaJonathan Chang – Leerink PartnersEric Joseph – J.P. MorganLaura Prendergast – Raymond James
Operator
Good day and thanks for standing by. Welcome to Revolution Medication’s Q3 2024 Earnings Convention Name. At the moment, all individuals are in a listen-only mode. After the speaker’s presentation, there might be a question-and-answer session. [Operator Instructions] Please be suggested that right this moment’s convention is being recorded.
I’d now like handy the convention over to your first speaker right this moment, Ryan Asay, Senior Vice President of Company Affairs. Please go forward.
Ryan Asay
Thanks, and welcome, everybody, to the third quarter 2024 earnings name. Becoming a member of me on right this moment’s name are Dr. Mark Goldsmith, Revolution Medication’s Chairman and Chief Government Officer; Dr. Steve Kelsey, our President of R&D; and Jack Anders, our Chief Monetary Officer. Dr. Wei Lin, our Chief Medical Officer, will be a part of us for the Q&A portion of right this moment’s name.
I want to inform you that sure statements we make throughout this name might be forward-looking as a result of such statements take care of future occasions and are topic to many dangers and uncertainties. Precise outcomes might differ materially from these within the forward-looking statements. For a full dialogue of those dangers and uncertainties, please evaluate our annual report on Type 10-Ok and our quarterly report on Type 10-Q which are filed with the U.S. Securities and Trade Fee. This
[ad_2]
Source link
